False Claims Act

False Claims Act
U.S. Government · Public domain · source
Name	False Claims Act
Enacted	1863
Jurisdiction	United States
Status	in force

False Claims Act

The False Claims Act is a United States federal statute that imposes liability on persons and entities that defraud United States programs. It includes a qui tam provision that allows private individuals to bring actions on behalf of the United States Department of Justice and share in recoveries. The statute has been applied in contexts involving Department of Defense, Department of Health and Human Services, Medicare, Medicaid, and other federal spending programs, and has shaped enforcement by the Supreme Court of the United States, United States Court of Appeals, and trial courts.

History

The act was enacted during the American Civil War in 1863 to combat wartime fraud against the Union Army and contractors supplying Union Navy efforts. Early enforcement involved suits by private relators modeled on English common law actions against false claims. Following P.R. Qui tam traditions, prominent mid-19th century cases involved contractors and supply chains servicing Fort Sumter and other military installations. The statute was amended during the 20th century, notably by the Public Law 99-562 amendments and the Fraud Enforcement and Recovery Act of 2009; those changes responded to scandals involving federal procurement, including cases tied to Halliburton, Boeing, and healthcare providers participating in Medicare and Medicaid programs. Judicial interpretation evolved through decisions by the United States Supreme Court and various circuit courts, producing doctrines addressing materiality, scienter, and jurisdiction under the Federal Rules of Civil Procedure.

Key Provisions

The statute creates liability for presenting or causing to be presented false or fraudulent claims for payment to the Treasury, or making false records to get such claims paid. It authorizes treble damages and civil penalties under the Civil Penalties Inflation Adjustment Act framework, and sets standards for pleading under the Federal Rules of Civil Procedure's Rule 9(b) for fraud. The act defines Qui tam relators' rights, the United States Department of Justice's right to intervene, and provisions limiting retaliation under False Claims Act retaliation provisions consistent with Whistleblower Protection Act principles. Amendments clarified standards for materiality after decisions from the United States Supreme Court and appellate courts, and legislative language addresses statutes of limitations and allocation of proceeds among relators, plaintiffs, and the United States Treasury.

Qui Tam Actions and Whistleblowers

Qui tam actions permit private parties, called relators, to sue on behalf of the United States of America and share a percentage of recoveries when the United States Department of Justice intervenes or declines. Relators often include former employees of contractors such as UnitedHealth Group, Pfizer, GlaxoSmithKline, or subcontractors to Department of Defense prime contractors like Lockheed Martin and Northrop Grumman. Successful qui tam litigation has been brought by plaintiffs in cases involving Medicare billing, Medicaid fraud, export controls violations involving Boeing, and procurement fraud with firms like Halliburton and KBR, Inc.. Protections against employer retaliation intersect with cases involving the National Labor Relations Board and civil suits enforced by the United States District Court.

Enforcement and Remedies

Enforcement is primarily led by the United States Department of Justice, often coordinated with agencies such as Department of Health and Human Services Office of Inspector General, Defense Contract Audit Agency, and the Department of Veterans Affairs Office of Inspector General. Remedies include treble damages, civil penalties under the Civil Penalties Inflation Adjustment Act, and disgorgement in coordination with the United States Attorney General. Settlements and judgments have involved corporate compliance agreements overseen by the Office of the Inspector General and corporate integrity agreements modeled after enforcement with firms like GlaxoSmithKline and Pfizer. Courts including the United States Court of Appeals for the Federal Circuit and the United States Court of Appeals for the Second Circuit have shaped doctrines on damages, materiality, and the scope of implied certification.

Notable Cases and Impact

Significant cases have included major settlements and decisions shaping substantive law and enforcement practice. High-profile recoveries involved HealthSouth Corporation, Abbott Laboratories, GlaxoSmithKline, and Siemens AG, producing multi-million-dollar and billion-dollar settlements that affected corporate compliance programs and prompted congressional oversight by committees such as the United States Senate Committee on Finance and the United States House Committee on Oversight and Reform. Judicial opinions from the United States Supreme Court and circuit courts clarified standards in landmark decisions, and enforcement actions have influenced procurement practices at the Department of Defense and billing practices across Medicare and Medicaid. Internationally, the act's principles have informed anti-fraud reforms in jurisdictions considering models like United Kingdom and Australia adaptations.

Criticisms and Reforms

Critics include defense contractors represented by firms such as Covington & Burling and Jones Day, healthcare providers, and trade groups like the U.S. Chamber of Commerce, which argue about overreach, qui tam abuse, and litigation costs. Proposed reforms debated in the United States Congress have addressed pleading standards, allocations to relators, and coordination with civil regulatory schemes like the Antitrust Division's enforcement and Securities and Exchange Commission proceedings. Legislative responses have focused on balancing incentives for whistleblowers represented by Relator attorneys against concerns raised in oversight hearings by the United States Senate Judiciary Committee and policy analyses from institutions such as the Brookings Institution and the Heritage Foundation.

Category:United States federal legislation